Lipid Nanoparticle Delivery of MicroRNAs for Treatment-Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma (GBM) and triple-negative breast cancer (TNBC) are limited by resistance to standard therapies, such as ionizing radiation and temozolomide, and lack effective targeting mechanisms, leading to poor prognosis and limited treatment options for these aggressive cancers.
Innovation Solution
Nanoparticles, specifically liposomes and lipid nanoparticles, encapsulating microRNAs like miR-603 or anti-miR-21, functionalized with a targeting moiety, are administered to specifically target and deliver therapeutic agents to cancer cells, enhancing radiation sensitivity and reducing cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard therapies (ionizing radiation and temozolomide) are used to treat glioblastoma, then initial treatment response is achieved, but tumor progression and recurrence occur due to development of resistance
Solution Approach 1:
The patent applies preliminary action by using nanoparticles to deliver microRNAs that preemptively sensitize cancer cells to radiation therapy before the actual treatment occurs. The microRNAs are delivered in advance to modulate gene expression and make the tumor cells more vulnerable to subsequent radiation, preventing resistance development rather than responding to it after it occurs.
Solution Approach 2:
The patent uses nanoparticles as an intermediary delivery system to transport microRNAs across the blood-brain barrier and into tumor cells. These nanoparticles act as mediators that facilitate the delivery of therapeutic agents specifically to the tumor site, enabling precise modulation of tumor cell sensitivity to radiation therapy.
2Adaptability or versatility
If conventional treatments are applied to triple-negative breast cancer, then general cancer therapy is provided, but effective targeting mechanisms are lacking leading to poor prognosis
Solution Approach 1:
The patent applies local quality by functionalizing nanoparticles with specific targeting moieties that recognize and bind to receptors uniquely or preferentially expressed on triple-negative breast cancer cells. This enables the therapeutic agent to be delivered specifically to the tumor tissue rather than systemically, achieving localized treatment effect with enhanced efficacy for this specific cancer subtype.
Solution Approach 2:
The patent employs parameter changes by modifying the physical and chemical properties of the nanoparticle delivery system, including size, surface charge, and surface functionalization, to optimize tumor penetration, cellular uptake, and targeted delivery to triple-negative breast cancer cells, thereby adapting the treatment to the specific characteristics of this aggressive cancer type.
Data Source
AI summary
This document relates to methods and materials for treating cancer. For example, this document provides nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs. In some cases, nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs can be administered to a mammal (e.g., a human) having cancer to treat the mammal.